Has NRG-CC009 changed your approach to offering SRS over HA-WBRT as the preferred treatment for patients with brain metastases from small cell lung cancer?
This question is part of our ASTRO 2026 collaboration, inspired by the Plenary Session Presentation "NRG-CC009: A Phase III Trial of Stereotactic Radiosurgery (SRS) vs. Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for Brain Metastases from Small Cell Lung Cancer (SCLC)" by Dr. Chad Rusthoven, MD
2 Answers
Mednet MemberInvited Expert
Radiation Oncology · University of Texas MD Anderson Cancer Center
Answered on
Yes, it has. The authors and NRG are commended for completing this pivotal trial. We were offering MDACC SRS in select cases based on an ongoing clinical trial there as well. NRG-CC009 trial will establish a standard for SRS as the preferred modality for patients with SCLC in cases where patient sel...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Radiation Oncology · The James Cancer Hospital and Solove Research Institute - The Ohio State Univ.
Answered on
We preferred SRS before the results of NRG-CC009, so we will continue this practice; it has affirmed our treatment choice in SRS upfront to speed the time to systemic therapy.
Join for free or sign in to see the full answer